M(1) and M(2) muscarinic acetylcholine receptor subtypes mediate Ca(2+) channel current inhibition in rat sympathetic stellate ganglion neurons.
Muscarinic acetylcholine receptors (mAChRs) are known to mediate the acetylcholine inhibition of Ca(2+) channels in central and peripheral neurons. Stellate ganglion (SG) neurons provide the main sympathetic input to the heart and contribute to the regulation of heart rate and myocardial contractility. Little information is available regarding mAChR regulation of Ca(2+) channels in SG neurons. The purpose of this study was to identify the mAChR subtypes that modulate Ca(2+) channel currents in rat SG neurons innervating heart muscle. Accordingly, the modulation of Ca(2+) channel currents by the muscarinic cholinergic agonist, oxotremorine-methiodide (Oxo-M), and mAChR blockers was examined. Oxo-M-mediated mAChR stimulation led to inhibition of Ca(2+) currents through voltage-dependent (VD) and voltage-independent (VI) pathways. Pre-exposure of SG neurons to the M(1) receptor blocker, M(1)-toxin, resulted in VD inhibition of Ca(2+) currents after Oxo-M application. On the other hand, VI modulation of Ca(2+) currents was observed after pretreatment of cells with methoctramine (M(2) mAChR blocker). The Oxo-M-mediated inhibition was nearly eliminated in the presence of both M(1) and M(2) mAChR blockers but was unaltered when SG neurons were exposed to the M(4) mAChR toxin, M(4)-toxin. Finally, the results from single-cell RT-PCR and immunofluorescence assays indicated that M(1) and M(2) receptors are expressed and located on the surface of SG neurons. Overall, the results indicate that SG neurons that innervate cardiac muscle express M(1) and M(2) mAChR, and activation of these receptors leads to inhibition of Ca(2+) channel currents through VI and VD pathways, respectively.
Yang
Qing
Q
Department of Anesthesiology, H187, Penn State College of Medicine, 500 University Dr., Hershey, PA 17033-0850, USA.
Sumner
Andrew D
AD
Puhl
Henry L
HL
Ruiz-Velasco
Victor
V
D000818:Animals; D002121:Calcium Channel Blockers / Q000494:pharmacology; D020864:Calcium Channels, N-Type / Q000502:physiology*; D002232:Carbocyanines; D003627:Data Interpretation, Statistical; D004594:Electrophysiology; D005455:Fluorescent Antibody Technique; D005456:Fluorescent Dyes; D005728:Ganglia, Sympathetic / Q000166:cytology* / Q000502:physiology*; D006321:Heart / Q000294:innervation; D008297:Male; D008856:Microscopy, Fluorescence; D018721:Muscarinic Agonists / Q000494:pharmacology; D009474:Neurons / Q000502:physiology*; D010095:Oxotremorine / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043643:Receptor, Muscarinic M1 / Q000502:physiology*; D043585:Receptor, Muscarinic M2 / Q000502:physiology*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020866:omega-Conotoxin GVIA / Q000494:pharmacology
D002121:Calcium Channel Blockers; D020864:Calcium Channels, N-Type; D002232:Carbocyanines; D005456:Fluorescent Dyes; D018721:Muscarinic Agonists; D043643:Receptor, Muscarinic M1; D043585:Receptor, Muscarinic M2; C024286:3,3'-dioctadecylindocarbocyanine; D010095:Oxotremorine; D020866:omega-Conotoxin GVIA